A Salicylic Acid-Based Hypoxia-Response Chemodynamic Nanomedicine Via Modulation of Immunosuppression Tumor Microenvironment for Enhanced Antitumor Immunotherapy

Kai Sun,Jiaying Yu,Jinzhong Hu,Jian Chen,Jia Song,Zhixin Chen,Zhuoer Cai,Zhuoxuan Lu,Liming Zhang,Zhifei Wang
DOI: https://doi.org/10.2139/ssrn.4058083
2022-01-01
Abstract:The delivery of salicylic acid or its derivatives to tumor tissue in the form of nanomedicine is critical for the studies on their potential synergistic mechanism in tumor therapy and chemoprevention considering the dangerous bleeding in the high-dose oral administration. To deepen the understanding of their role in adjusting immunosuppression tumor microenvironment (ITM), herein, we firstly developed a hypoxia-sensitive Fe-5,5'-azosalicylic acid nanoscale coordination polymer nanomedicines (FeNCPs) via a 'old drugs new tricks' strategy for synergistic chemodynamic therapy (CDT) and remodulation of ITM to elevate antitumor immunotherapy effect. PEGylated FeNCPs could be reductively cleaved to release 5-aminosalicylic acid (5-ASA) and ferric ions by azo-reductase under hypoxic conditions, which could induce tumor cell death by Fenton reaction-catalysis enhanced CDT and 5-ASA-converted carboxylquinone to promote the production of •OH. Meanwhile, cyclooxygenase-2 (COX-2) and its enzymatic product prostaglandin E2 (PGE2), as immune negative regulatory molecules, can promote tumor progression and immune tolerance. The released 5-ASA as a COX inhibitor could suppress the expression of PGE2, and Fe3+ was employed to reeducate M2-like tumor-associated macrophages (TAMs) to M1-like phenotype, which could initiate antitumor immune response to reach better antitumor immunotherapy. This work broadens the application of salicylic acid derivatives in antitumor immunotherapy, and provides a new strategy for their “old drugs new tricks”.Funding Information: This work was financially supported by the National Natural Science Foundation of China (81771976), the National Key Research and Development Program of China (Grant 2018YFC1901202), the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science, SKLPBS2134).Declaration of Interests: The authors declare no conflict of interest.Ethics Approval Statement: All animal experimental procedures were approved by the Experimental Animal Ethics Committee of Southeast University guidelines (China), followed the institutional guidelines of the Experimental Animal Ethics Committee of Southeast University (China) and performed in compliance with the regulations for the Administration of Affairs Concerning Experimental Animals of China.
What problem does this paper attempt to address?